United Therapeutics (NASDAQ: UTHR) announced its earnings results on Tuesday. The company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.40. The company had revenue of $243.82 million for the quarter, compared to the consensus estimate of $233.41 million.
A number of analysts have recently weighed in on UTHR shares. Analysts at Ladenburg Thalmann raised their price target on shares of United Therapeutics from $59.00 to $69.00 in a research note to investors on Tuesday, February 19th. On the ratings front, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note to investors on Monday, February 4th. Finally, analysts at Guggenheim initiated coverage on shares of United Therapeutics in a research note to investors on Wednesday, January 23rd. They set a “neutral” rating on the stock.
Four equities research analysts have rated the stock with a buy rating, six have given a hold rating, and two have issued a sell rating to the company. United Therapeutics presently has an average rating of “hold” and a consensus target price of $54.00.
United Therapeutics (UTHR) opened at 57.66 on Tuesday. United Therapeutics (UTHR) has a 1-year low of $40.34 and a 1-year high of $59.00. The stock’s 50-day moving average is currently $53.90. The company has a market cap of $2.929 billion and a price-to-earnings ratio of 11.59.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.